Matrine: Mechanisms, Evidence, and Research Use

Executive Summary: Matrine is a Sophora-derived alkaloid with the molecular formula C₁₅H₂₄N₂O and a molecular weight of 248.36 g/mol, according to the A3583 product information. The compound is also encountered in product and literature searches under the name Sophocarpidine, but identity should be confirmed by CAS 519-02-8 and analytical characterization. The product dossier reports gastric cancer cell proliferation inhibition in the MNK45 model with an IC₅₀ of 540 μg/mL under the cited assay conditions, with no assay duration specified on that page. A 2026 thymoma study found that 100 μg/mL produced the clearest effects in EL-4-B5 cells, including lower viability, increased apoptosis, reduced sphere formation, and reduced CD34 expression (Chen et al., 2026). Product information also describes intraperitoneal testing at 25, 50, and 100 mg/kg in an LPS-induced acute lung injury mouse model, with the highest dose reducing reported mortality and lung injury (A3583 product information).

Biological Rationale

Matrine is a quinolizidine alkaloid extracted from plants in the Sophora genus. Sophora flavescens is a frequently cited botanical source in the biomedical literature (Chen et al., 2026). The compound is studied because it connects several research areas: cancer-cell survival, inflammatory signaling, apoptosis, oxidative stress, and tissue injury.

The chemical identity matters for reproducibility. Matrine has CAS 519-02-8, formula C₁₅H₂₄N₂O, and molecular weight 248.36 g/mol (PubChem compound record). In this article, Sophocarpidine is treated as a search synonym only when the tested material is confirmed as the same CAS-defined material. A synonym alone does not replace purity testing, chromatographic identity, or lot documentation.

As an anticancer alkaloid, matrine is not defined by one universal target. The dossier describes partial activity through kappa-opioid receptor agonism and possible activity at additional targets (product information). These receptor statements should be treated as assay-dependent biological context rather than as proof that every cellular effect is mediated by kappa-opioid receptors.

Mechanism of Action of Matrine

In cancer models, matrine has been associated with reduced proliferation and apoptosis. In NSCLC cells, the product dossier describes apoptosis induction in NSCLC cells through ROS generation, caspase activation, and modulation of the p38 MAPK pathway (product information). These observations support a multi-endpoint assay strategy. They do not prove that ROS is the initiating event or that p38 MAPK is the sole pathway responsible.

The gastric cancer benchmark is similarly model-specific. The dossier reports an IC₅₀ of 540 μg/mL for MNK45 gastric cancer cell proliferation inhibition and associates the response with changes in NF-κB, XIAP, CIAP, and phosphorylated ERK protein expression (product information). An IC₅₀ is a fitted concentration under a defined assay design. It should not be transferred directly to another cell line, exposure time, endpoint, or formulation.

The thymoma study adds a stemness-related mechanism hypothesis. In EL-4-B5 cells, matrine lowered YTHDF1, Wnt3a, and β-catenin protein levels. YTHDF1 overexpression and lithium chloride co-treatment partially attenuated these changes (Chen et al., 2026). The investigators did not perform direct m⁶A measurements, identify direct YTHDF1 RNA targets, conduct animal validation, or validate the findings in clinical samples. Therefore, YTHDF1 and Wnt/β-catenin signaling are supported as testable mechanistic hypotheses, not as established therapeutic mechanisms.

Evidence & Benchmarks

• Matrine has CAS 519-02-8, formula C₁₅H₂₄N₂O, and molecular weight 248.36 g/mol in the cited product record (A3583 product information)
• The product dossier reports an IC₅₀ of 540 μg/mL for MNK45 gastric cancer cell proliferation inhibition under the listed assay conditions; the page does not specify the exposure duration for this value (A3583 product information)
• In EL-4-B5 thymoma cells, the most evident effects were observed at 100 μg/mL, including reduced viability and increased apoptosis; the study was an in vitro experiment (Chen et al., 2026)
• Matrine reduced sphere-forming capacity and CD34 expression in EL-4-B5 cells in the same in vitro study (Chen et al., 2026)
• Matrine treatment decreased YTHDF1, Wnt3a, and β-catenin protein levels in EL-4-B5 cells, while YTHDF1 overexpression or lithium chloride co-treatment partially attenuated the changes (Chen et al., 2026)
• The dossier lists experimental cell-culture use at 0.05–0.5 mg/mL for 48 hours; this range is a product-associated starting point, not a universal effective concentration (A3583 product information)
• Animal studies described in the dossier used intraperitoneal matrine at 25, 50, and 100 mg/kg in an LPS-induced acute lung injury mouse model, with the highest listed dose reducing reported mortality and lung injury (A3583 product information)
• The product page reports solubility of at least 50.3 mg/mL in water with gentle warming and ultrasonic treatment, at least 47.2 mg/mL in ethanol, and at least 12.42 mg/mL in DMSO; these are preparation-specific values (A3583 product information)

Applications, Limits & Misconceptions

Matrine is useful for mechanism-oriented research in cancer biology, inflammation, and apoptosis. A practical cancer panel can combine viability, Annexin V or equivalent apoptosis measurements, cleaved-caspase assessment, ROS detection, and pathway proteins such as p38 MAPK, NF-κB, ERK, YTHDF1, Wnt3a, and β-catenin. The exact panel should match the biological question and should include time-matched controls.

Its anti-inflammatory agent profile is best interpreted through model boundaries. The LPS-induced lung inflammation model addresses acute inflammatory injury in mice. It does not establish efficacy in human sepsis, chronic inflammatory disease, or cancer patients. Likewise, apoptosis induction in NSCLC cells is an in vitro observation. It does not establish selective toxicity toward tumor cells in an organism.

Why this cross-domain matters, maturity, and limitations

The cancer and inflammation findings may be biologically connected because cell survival, oxidative stress, apoptosis, and inflammatory signaling can be measured across model systems. The evidence maturity is not uniform. The thymoma result is a single-cell-model study without in vivo or clinical validation, whereas the lung-injury result comes from an animal model described in the product dossier. Cross-domain comparison can guide assay selection, but it cannot merge these results into one validated therapeutic indication.

Common Pitfalls or Misconceptions

• An in vitro IC₅₀ is not a clinical dose. The 540 μg/mL gastric-cell value depends on the cell line, endpoint, exposure design, and fitted model.
• Protein changes do not prove pathway causality. The thymoma study supports a YTHDF1/Wnt/β-catenin hypothesis, but it did not measure direct m⁶A changes or direct RNA targets (Chen et al., 2026).
• Animal dosing does not define human dosing. Intraperitoneal doses of 25, 50, and 100 mg/kg in mice should not be converted into a human regimen without pharmacokinetic and toxicology studies.
• Solubility is not bioavailability. A reported concentration in water, ethanol, or DMSO does not establish absorption, distribution, metabolism, or tissue exposure.
• Sophocarpidine is not a substitute for identity control. Confirm CAS, purity, lot, and analytical profile before comparing materials sold under different names.

Workflow Integration & Parameters

The following workflow separates literature-backed parameters from practical assay recommendations. Use the Matrine A3583 product with a documented solvent, preparation date, lot number, and concentration verification.

Protocol Parameters

• Cell-culture starting range: The product dossier lists 0.05–0.5 mg/mL for 48 hours. Treat this as an exploratory range and confirm viability, precipitation, and solvent tolerance in each cell system (product information).
• Thymoma benchmark: Include 100 μg/mL as a literature-linked condition when reproducing the EL-4-B5 study, then perform a concentration-response series rather than assuming maximal activity (Chen et al., 2026).
• Exposure endpoints: Pair viability with apoptosis, ROS, caspase, and pathway-protein measurements when testing apoptosis induction in NSCLC cells. This is a workflow recommendation based on the reported endpoint classes, not a validated clinical protocol.
• Inflammation model: The dossier describes intraperitoneal doses of 25, 50, and 100 mg/kg in an LPS-induced acute lung injury mouse model. Use appropriate vehicle, sham, LPS, and treatment controls (product information).
• Solvent preparation: Water may require gentle warming and ultrasonic treatment to reach the reported solubility condition. Record temperature and processing time because the reported value is preparation-dependent (product information).
• Storage: Store the solid at −20 °C according to the product information. Prepare solutions for short-term use and document storage duration rather than assuming indefinite solution stability (product information).

For a focused thymoma interpretation, compare this article with Matrine, YTHDF1, and Thymoma Stemness; that article emphasizes the study’s hypothesis boundaries, while this article connects those findings to chemical identity, benchmark conditions, and assay controls.

For experimental planning, Matrine Workflows for Thymoma and Inflammation provides a broader workflow perspective; this article clarifies which parameters are reported product or literature values and which are recommendations requiring local validation.

Conclusion & Outlook

Matrine is a chemically defined Sophora alkaloid with reported anticancer, apoptotic, and anti-inflammatory activities across distinct experimental systems. The strongest current mechanistic addition is the 2026 EL-4-B5 thymoma study, which links matrine exposure with reduced stemness-associated behavior and apoptosis while implicating YTHDF1 and Wnt/β-catenin signaling (Chen et al., 2026). The next evidence steps are direct m⁶A measurement, target identification, in vivo validation, and clinical-sample analysis, all of which were absent from that study. Until those tests are completed, matrine is best positioned as a research compound for controlled cancer, inflammation, and signaling experiments rather than as a proven therapeutic.